Daniele VF Tauriello

Dr. Daniele VF Tauriello

Radboudumc
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
DSDiana Stork
Diana Stork
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
JBJordi Badia-Ramentol
Jordi Badia-Ramentol
EBEduard Batlle
Eduard Batlle
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers1,2. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration3, low type 1 T-helper cell (TH1) activity and reduced immune cytotoxicity2 or increased TGFβ levels4 predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden5, T-cell exclusion3 and TGFβ-activated stroma4,6,7. Inhibition of the PD-1–PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1–PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the TH1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.

1 November 2012 in Cancer Cell
Verified
Journal Article
Closed access
ACAlexandre Calon
Alexandre Calon
EEElisa Espinet
Elisa Espinet
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
MIMar Iglesias
Mar Iglesias
EBEduard Batlle
Eduard Batlle

23 February 2015 in Nature Genetics
Verified
Journal Article
Closed access
ACAlexandre Calon
Alexandre Calon
ELEnza Lonardo
Enza Lonardo
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
EEElisa Espinet
Elisa Espinet
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle

10 February 2016 in Nature
Verified
Journal Article
Closed access
HFHenner F. Farin
Henner F. Farin
IJIngrid Jordens
Ingrid Jordens
MMMohammed H. Mosa
Mohammed H. Mosa
OBOnur Basak
Onur Basak
JKJeroen Korving
Jeroen Korving
HCHans Clevers
Hans Clevers

20 October 2021 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
ESElena Sancho
Elena Sancho
EBEduard Batlle
Eduard Batlle

1 April 2014 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
ACA. Calon
A. Calon
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
EBE. Batlle
E. Batlle